Topiramate for the management of methamphetamine dependence: a pilot randomized, double-blind, placebo-controlled trial

To date, no medication has been approved as an effective treatment for methamphetamine dependence. Topiramate has attracted considerable attention as a treatment for the dependence on alcohol and stimulants. Therefore, this study aimed to evaluate the effect of topiramate for methamphetamine depende...

Full description

Saved in:

Bibliographic Details
Published in:	Fundamental & clinical pharmacology Vol. 30; no. 3; pp. 282 - 289
Main Authors:	Rezaei, Farzin, Ghaderi, Ebrahim, Mardani, Roya, Hamidi, Seiran, Hassanzadeh, Kambiz
Format:	Journal Article
Language:	English
Published:	England Blackwell Publishing Ltd 01-06-2016
Subjects:	Adult Amphetamine-Related Disorders - diagnosis Amphetamine-Related Disorders - drug therapy Amphetamine-Related Disorders - epidemiology Central Nervous System Stimulants - adverse effects clinical trial Disease Management Double-Blind Method Follow-Up Studies Fructose - analogs & derivatives Fructose - therapeutic use Humans Iran - epidemiology Male Methamphetamine - adverse effects methamphetamine dependence Pilot Projects topiramate clinical trial methamphetamine dependence topiramate
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	To date, no medication has been approved as an effective treatment for methamphetamine dependence. Topiramate has attracted considerable attention as a treatment for the dependence on alcohol and stimulants. Therefore, this study aimed to evaluate the effect of topiramate for methamphetamine dependence. This study was a double‐blind, randomized, placebo‐controlled trial. In the present investigation, 62 methamphetamine‐dependent adults were enrolled and randomized into two groups, and received topiramate or a placebo for 10 weeks in escalating doses from 50 mg/day to the target maintenance dose of 200 mg/day. Addiction severity index (ASI) and craving scores were registered every week. The Beck questionnaire was also given to each participant at baseline and every 2 weeks during the treatment. Urine samples were collected at baseline and every 2 weeks during the treatment. Fifty‐seven patients completed 10 weeks of the trial. There was no significant difference between both groups in the mean percentage of prescribed capsules taken by the participants. At week six, the topiramate group showed a significantly lower proportion of methamphetamine‐positive urine tests in comparison with the placebo group (P = 0.01). In addition, there were significantly lower scores in the topiramate group in comparison with the placebo group in two domains of ASI: drug use severity (P < 0.001) and drug need (P < 0.001). Furthermore, the craving score (duration) significantly declined in the topiramate patients compared to those receiving the placebo. In conclusion, the results of this trial suggest that topiramate may be beneficial for the treatment of methamphetamine dependence.
Bibliography:	ArticleID:FCP12178 istex:8DB0AC37F3AC060188CE42C2C47962DDAB2707EA ark:/67375/WNG-MF9MN8QT-6 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-News-1 ObjectType-Feature-3 content type line 23 ObjectType-Article-1 ObjectType-Feature-2
ISSN:	0767-3981 1472-8206
DOI:	10.1111/fcp.12178